Genetics of Pharmacogenomics
Pharmacogenomics studies how genetic variants influence responses to medications. Variants in drug-metabolising enzymes, transporters, and drug targets underlie individual differences in drug efficacy, dosing requirements, and adverse effect risk.
This page is for educational and informational purposes only. Not a diagnostic tool. Always consult a qualified healthcare provider.
What is Pharmacogenomics?
Pharmacogenomics is one of the most clinically actionable areas of genetics — identifying variants that predict drug response differences with sufficient certainty to guide prescribing decisions. Key areas include CYP450 enzyme variants affecting drug metabolism rates, transporter variants affecting drug distribution, and target variants affecting drug efficacy. In the context of Long COVID management — where patients often trial multiple symptomatic therapies — pharmacogenomic information may support more rational drug selection and dosing. The FDA has approved pharmacogenomic labelling for over 200 medications.
Biological pathways commonly discussed in relation to Pharmacogenomics
Research into Pharmacogenomics and Drug Response Genetics has highlighted several biological pathways that may be relevant. Genetic variants within these pathways may influence individual susceptibility, symptom severity, or the trajectory of the condition.
Cyp450 Pharmacogenomics
CYP2D6, CYP2C19, CYP2C9, and CYP3A4/5 metabolise the majority of commonly prescribed medications. Poor metaboliser status can cause drug toxicity; ultra-rapid metaboliser status can reduce efficacy.
Transporter Pharmacogenomics
ABCB1 (P-glycoprotein) affects drug tissue distribution and CNS penetration. SLCO1B1 influences statin liver uptake — the rs4149056 variant is specifically associated with statin myopathy risk.
Target Pharmacogenomics
VKORC1 determines warfarin sensitivity; DPYD variants identify fluoropyrimidine toxicity risk; TPMT/NUDT15 variants predict thiopurine toxicity. These are FDA-approved pharmacogenomic biomarkers.
Phase2 Pharmacogenomics
NAT2 slow acetylator status affects isoniazid and other drug responses. UGT1A1 variants affect irinotecan toxicity and direct bilirubin processing. These Phase II enzyme variants are clinically important.
Key genes studied in relation to Pharmacogenomics
The following genes have been studied in relation to Pharmacogenomics and Drug Response Genetics. These genes span the biological pathways most commonly discussed in this area of research.
11 genes total studied in relation to Pharmacogenomics across the ChronicDNA dataset.
Genetic variants commonly discussed
The following genetic variants (SNPs) are found in genes that have been studied in relation to Pharmacogenomics. Each variant represents a position in the genome where individuals may carry different alleles.
24 variants total across genes studied in relation to Pharmacogenomics.
How personal DNA data may provide educational insights
Consumer DNA files from 23andMe, AncestryDNA, and MyHeritage contain raw SNP data. When you upload your file to ChronicDNA, the analysis engine checks your genotype against a curated panel of 80+ genes selected for their relevance to Long COVID, ME/CFS, and connected biological pathways - some of which may relate to areas such as Pharmacogenomics.
This is not a diagnostic service. Genetic variants do not determine whether you have Pharmacogenomics, nor do they predict your clinical outcomes. The report is educational - it explains which variants you carry, what the research says about them, and how they fit into the biological pathways most relevant to chronic illness. All results should be discussed with a qualified healthcare provider.
Related conditions and pathways
Pharmacogenomics shares biological pathways and genetic associations with the following related conditions and areas of research.
Frequently asked questions
What is pharmacogenomics?
Pharmacogenomics studies how genetic variants influence drug responses — including metabolism rate, efficacy, and adverse effect risk. It allows prediction of individual drug responses from genetic data, enabling more personalised prescribing.
Which pharmacogenomic variants are most clinically established?
FDA-approved pharmacogenomic markers include CYP2D6/CYP2C19 for antidepressants and antiplatelet drugs, CYP2C9/VKORC1 for warfarin, SLCO1B1 for statin myopathy, DPYD for fluoropyrimidines, TPMT/NUDT15 for thiopurines, and HLA-B*5701 for abacavir hypersensitivity.
Is pharmacogenomic testing useful for Long COVID patients?
Long COVID patients often trial multiple symptomatic medications. Pharmacogenomic information about CYP2D6, CYP2C19, and related genes may help predict responses to medications used symptomatically — including certain antidepressants, antihistamines, and antinausea drugs. Any changes should be made with healthcare provider guidance.
Can consumer DNA data provide pharmacogenomic insights?
Consumer DNA arrays capture many pharmacogenomically relevant variants. ChronicDNA analyses these for educational context — formal pharmacogenomic testing and clinical interpretation should be performed through accredited laboratories and with prescriber involvement.
Explore DNA insights
If you already have DNA data from 23andMe, AncestryDNA, or MyHeritage, upload your raw file to ChronicDNA and receive a personalised educational report covering genes studied in relation to Pharmacogenomics and connected biological pathways.
Get Your Personalised DNA ReportInformational and educational only · Not a diagnostic tool · GDPR compliant
11 genes · 24 variants analysed in relation to Pharmacogenomics